Summary:
Osimertinib stopped responding or did not respond to treatment? Try the SAFFRON study! This may be the research study for you.
We encourage all participants to consult their medical team before participating in research studies.
Criteria:If you have locally advanced or metastatic NSCLC, tested positive for EGFR and MET, and your Osimertinib treatment stopped responding, you may qualify for this study.
Qualified Participants May Receive:
Compensation and transportation are available.